Oral calcium channel blockers (CCBs) for the treatment of hypertension including benzothiazepines, dihydropyridines, and diphenylalkylamines.
FDA-Approved treatment options for individuals with ovarian cancer including dosing.
Survival improvements were noted in brain and nervous system cancers, colorectal cancers, and lung cancer.
Findings compared with two years of extended adjuvant anastrozole in postmenopausal women with hormone-receptor-positive breast cancer.
For men and women with high genetic risk, five-year cancer incidence down significantly with a favorable lifestyle.
Pyrotinib plus capecitabine bested lapatinib plus capecitabine in a phase 3 trial.
About 31% of the articles analyzed contained information classified as harmful.
Combination ipilimumab and nivolumab reduced the risk of death by 56% when compared with fotemustine monotherapy.
Survey-based study determined the association between patients’ perception of aesthetic outcome and psychosocial function after undergoing ablation with this complex procedure.
Multiple myeloma (MM) is not a disease with a known cure, but recent studies have suggested that focusing on boosting immunity in patients with MM may help their chances at longer-term survival. What are these immunity-focused treatment options?
The disparity is due to the greater prevalence of fibroids and nonendometrioid histologic type in Black women, according to researchers.
Hispanics have higher MM-related in-hospital mortality; recent decline seen in in-hospital mortality for all except NH-Blacks.
Dr Alan Lyss reviews studies of KRAS G12C mutations in metastatic colorectal cancer.
Oxaliplatin-based hyperthermic intraperitoneal chemotherapy showed no OS benefit compared with cytoreductive surgery in patients with colorectal peritoneal metastases.
In the B-43 phase 3 trial, researchers did not achieve the objective of a 36% reduction in ipsilateral breast cancer rate with the addition of trastuzumab to radiotherapy.
Treatment-related toxicities were less likely with the lobaplatin-based regimen.
Chemotherapeutic and biologic agents for the treatment of non-small cell lung cancer (NSCLC).
RSK4-targeting floxacins could boost the efficacy of chemotherapy.
Surgery was an independent predictor of overall survival.
Aspirin may prevent distant metastases, according to researchers.
Black men less likely than White men to undergo prostatectomy despite similar COVID-19 risk factors, biopsy Gleason grade groups.
Efficacy and toxicity outcomes were similar with calaspargase and pegaspargase.
Researchers sought to determine whether cryopreservation of unrelated donor hematopoietic stem cells would affect outcomes in patients who underwent HSCT since the COVID-19 pandemic.
Risk of CVD death is lower with PCNSL than with extra-central nervous system lymphoma; however, the risk with this rare non-Hodgkin lymphoma is uncertain.
Researchers sought to clarify the current treatment strategies and challenges for patients with chronic lymphocytic leukemia.
FDA-approved oral and injectable treatment options for breast cancer.
Colorectal cancer treatment regimen chart.
A 1:1 ratio of THC to CBD proved superior to a 4:1 ratio.
Pembrolizumab improved pathologic complete response rates and event-free survival.
The approval was based on data from the phase 3 KEYNOTE-522 trial, which included 1174 patients with newly diagnosed previously untreated high-risk early-stage TNBC.
Mandatory vaccination is especially crucial to protect vulnerable people, including unvaccinated children and those with weakened immune systems.
The overall survival rate at 1 year was 86% with vandetanib and 70% with cabozantinib.
Therapy intensification with carboplatin improved five-year event-free survival in children with high-risk group 3 medulloblastoma only.
Living in rural counties and living farther from reporting hospital detrimental for adolescents and young adults with cancer.
Wound care dressings and cleansers including hydrocolloid occlusive dressings, wet-to-dry dressings, hydrogels, foam dressings, odor-controlling dressings, and xerogels.
Progestin and estrogen content of oral contraceptives (birth control pills) chart.
Researchers sought to determine whether subcutaneous daratumumab would require less HCP time and would be a more efficient method for administering the drug.
The findings support current management strategies for cancer patients, according to researchers.
The study showed differences by cancer type and race/ethnicity.
Phase 2 trial results supported the approval of cemiplimab for this patient group.
Genetic variations in the PAX8, CLPTM1L, and HLA genes were found to be associated with a high risk of developing cervical cancer.
Significant reductions seen for global distress index, psychological symptoms, physical symptoms of Memorial Symptom Assessment Scale.
A list of treatment options for HIV infection.
Phase 3 results refute findings from retrospective studies.
Two experts discuss the future of colorectal cancer screening and lessons learned during the era of COVID-19.
The antibody-drug conjugate demonstrated durable antitumor activity in heavily pretreated patients.
The combination improved progression-free survival.
More than half of patients responded, and responses deepened over time.
Increased risks seen for survivors of leukemia, lymphoma, multiple myeloma, skin cancer, and lung cancer in subgroup analyses.
The nomograms predicted overall and progression-free survival.
There was no benefit to extending zoledronate treatment beyond 2 years.
Education, communication, and coordination are key.
Stereotactic body radiotherapy more than doubled the complete response rate.
The full approval was based on data from the confirmatory phase 3 KEYNOTE-775 trial.
Researchers sought to determine whether combination therapies with carfilzomib would be feasible for patients with relapsed/refractory multiple myeloma.
The results raise concern about potential local tumor spill, according to researchers.
The overall response rate was 100%.
Researchers sought to assess the disease-specific costs for Medicare recipients with multiple myeloma.
Platinum-based chemotherapy should remain the standard of care, according to researchers.
Therapeutically actionable germline variants were found in 8% of patients with advanced cancers.
The combination bested sorafenib.
Patients with parathyroid carcinoma after localized resection for a presumed benign indication should undergo close monitoring for recurrence rather than radical surgery.
FOLFOX provided a benefit over active symptom control.
A retrospective study revealed age-based risks for toxicities in patients with NHL treated with high-dose chemotherapy and autologous hematopoietic cell transplantation.
There was no improvement in progression-free or overall survival.
A single-center study found anti-COVID-19 protection lowest in patients with MM at 2 weeks after their second BNT162b2 mRNA shot than did patients with myeloproliferative malignancies, and was highest in older patients without cancer.
Social isolation and lack of safety at home associated with distress; unmet needs also linked to treatment interruption.
Researchers sought to determine whether plasma biomarkers may help enhance CAR-T therapy for patients with multiple myeloma.
The current scientific evidence may not be generalizable to underrepresented groups.
Immune-related adverse events were associated with improved survival outcomes.
The 5-year survival rate was longer with CPX-351 than with conventional chemotherapy.
Overall survival was superior with donafenib.
In 2020, an estimated 4.1 percent of all new cancer cases globally attributed to alcohol consumption.
Researchers sought to determine the real-world renal function and outcomes for patients with multiple myeloma according to type of treatment and line of therapy.
In a trial of men who volunteered for PSA screening, detection of clinically insignificant tumors and benign findings were reduced when prostate biopsy was performed only in those with positive MRI results.
When researchers combined clinical features with BRAF mutant allele fraction, patients could be divided into 3 risk groups that were significantly associated with survival.
The 5-year survival rate was superior with pembrolizumab.
Progression-free and overall survival outcomes were similar with and without ofatumumab.
Investigators zero in on mortality risk factors in patients with cancer who contract COVID-19.
A dose-reduction strategy in patients with CP-CML receiving dasatinib was shown to be feasible and may reduce adverse effects in these patients.
Photodynamic diagnosis cystoscopy demonstrates greater sensitivity in the detection of BCG-refractor bladder tumors compared with standard white light cystoscopy.
Geographic location of radiology practice, breast subspecialization, performing diagnostic mammography tied to radiologist performance.
Researchers in The Netherlands compared the surgical approaches in patients with muscle-invasive or high-risk nonmuscle-invasive bladder cancer.
Although nearly all metrics improved for racial-ethnic minorities, recent breast cancer-related mortality in Florida still higher in Black women.
Ideal patient selection for a deferred cytoreductive nephrectomy should include an assessment of Memorial Sloan Kettering Cancer Center risk score, according to investigators.
Researchers sought to determine whether poorer health-related quality of life would be linked to responses about pain severity in patients with multiple myeloma.
Early results support a fully-powered trial of 18F-PSMA PET/CT for prostate cancer detection, according to the investigators.
Compared with before the pandemic, men undergoing radical prostatectomy during the pandemic were more likely to have extraprostatic disease, according to investigators.
During a residential rehabilitation program, researchers interviewed participants to determine their supportive care and rehabilitation needs.
72 percent of low-income, uninsured, or publicly insured women perceived financial barriers to screening.
Among patients with stage I HER2+ breast cancer, adjuvant treatment with T-DM1 was associated with “excellent” 3-year iDFS, but was not associated with fewer clinically relevant toxicities compared with paclitaxel plus trastuzumab.
Children treated for neuroblastoma developed myeloid neoplasms with specific platinum chemotherapy-associated mutation signatures.
Cemiplimab monotherapy improved OS and PFS compared with chemotherapy in patients with advanced NSCLC with PD-L1 of at least 50%.
The results suggest a link, but more research is needed.
Before PDD TURBT can be adopted into clinical practice, a large pragmatic trial is needed, according to investigators.
Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
A final analysis of the TITAN trial shows that apalutamide vs placebo added to ADT significantly lowers the risk of death and castration-resistant disease in men with metastatic castration-sensitive prostate cancer.
Trial involving seven patients with locally advanced bladder cancer shows concurrent CON with radiation therapy feasible in Australia.
Use of clomiphene citrate or gonadotropins, alone or in combination, not associated with increased risk for breast cancer.